Jump to content

Adrenoleukodystrophy

From Wikipedia, the free encyclopedia
For the autosomal recessive, neonatal onset disease, seeNeonatal adrenoleukodystrophy.
Adrenoleukodystrophy
Other namesX-linked adrenoleukodystrophy, ALD, X-ALD, Siemerling–Creutzfeldt disease, bronze Schilder disease
White matter,with reduced volume and increased signal intensity. The anterior white matter is spared. Features are consistent with X-linked adrenoleukodystrophy.
Pronunciation
SpecialtyMedical genetics
TypesX-Linked ALD

Adrenoleukodystrophy(ALD) is adiseaselinked to theX chromosome.It is a result offatty acidbuildup caused by failure ofperoxisomal fatty acid beta oxidationwhich results in the accumulation ofvery long chain fatty acidsin tissues throughout the body. The most severely affected tissues are themyelinin thecentral nervous system,theadrenal cortex,and theLeydig cellsin the testes. The long chain fatty acid buildup causes damage to themyelin sheathof theneuronsof the brain, resulting inseizuresand hyperactivity. Other symptoms include problems in speaking, listening, and understanding verbal instructions.

Clinically, ALD presents as a heterogeneous disorder, showing several distinctphenotypes,and no clear pattern ofgenotype–phenotype correlation.As an X-linked disorder, ALD presents most commonly in males; however, approximately 50% ofheterozygotefemales show some symptoms later in life. Approximately two-thirds of ALD patients will present with the childhood cerebral form of the disease, which is the most severe form. It is characterized by normal development in early childhood, followed by rapid degeneration to avegetative state.The other forms of ALD vary in timing of onset and in clinical severity, ranging from adrenal insufficiency alone to progressive paraparesis in early adulthood.

ALD is caused by mutations inABCD1,a gene located on theX chromosomethat codes for ALD, a peroxisomalmembrane transporter protein.The exact mechanism of the pathogenesis of the various forms of ALD is not known. Biochemically, individuals with ALD show very high levels of unbranched, saturated, very long chain fatty acids, particularlycerotic acid(26:0). The level of cerotic acid in plasma does not correlate with clinical presentation. Treatment options for ALD are limited. For the childhood cerebral form,stem cell transplantandgene therapyare options if the disease is detected early in the clinical course. Adrenal insufficiency in ALD patients can be successfully treated. ALD is the most common peroxisomal inborn error of metabolism, with an incidence estimated between 1:18,000 and 1:50,000. It does not have a significantly higher incidence in any specific ethnic group.

Signs and symptoms

[edit]

ALD can present in different ways. The different presentations are complicated by the pattern ofX-linked recessiveinheritance. There have been sevenphenotypesdescribed in males withABCD1mutations and five in females.[1]Initial symptoms in boys affected with the childhood cerebral form of ALD include emotional instability,hyperactivityand disruptive behavior at school. Older patients affected with the cerebral form will present with similar symptoms. Untreated, cerebral ALD is characterized by progressive demyelination leading to avegetative stateand death.[2]Adult males with an adrenomyeloneuropathy presentation typically present initially with muscle stiffness,paraparesisand sexual dysfunction.[3]All patients with clinically recognized ALD phenotypes are at risk for adrenal insufficiency.[2]There is no reliable way to predict which form of the disease an affected individual will develop, with multiple phenotypes being demonstrated within families.[4]Onset of adrenal insufficiency is often the first symptom, appearing as early as two years of age.[3]

Male adrenoleukodystrophy phenotypes

[edit]
Male adrenoleukodystrophy phenotypes[1]
Phenotype Description Onset Approximate relative frequency
Childhood cerebral Progressive neurodegenerative decline, leading to a vegetative state without treatment 3–10 years 31–35%
Adolescent Similar to childhood cerebral, with a slower progression 11–21 years 4–7%
Adrenomyeloneuropathy (AMN) Progressiveneuropathy,paraparesis;approximately 40% progress to cerebral involvement 21–37 years 40–46%
Adult cerebral Dementia,behavioral disturbances, similar progression to childhood cerebral form, but without preceding AMN phenotype Adulthood 2–5%
Olivo-ponto-cerebellar Cerebral andbrain steminvolvement Adolescence to adulthood 1–2%
"Addison diseaseonly " Adrenal insufficiency Before 7.5 years Up to 50% in childhood, varies with age
Asymptomatic No clinical presentation, further studies can reveal subclinical adrenal insufficiency or mild AMN phenotype Most common phenotype in boys under four years of age Proportion of asymptomatic patients decreases with age

Female adrenoleukodystrophy phenotypes

[edit]
Female adrenoleukodystrophy phenotypes[1]
Phenotype Description Onset Approximate relative frequency
Asymptomatic No neurologic or adrenal involvement Most women under 30 do not have any neurologic involvement Diminishes with age
Mild myelopathy Increased deep tendon reflexes, sensory changes in lower extremities Adulthood Approximately 50% of women over 40 years of age
Moderate to severe myeloneuropathy Similar to male AMN phenotype, but later onset and milder presentation Adulthood Approximately 15% of women over 40 years of age
Cerebral involvement Progressive dementia and decline Rare in childhood, more common in adults ~2%
Adrenal involvement Primary adrenal insufficiency Any age ~1%

Genetics

[edit]

ALD is caused by mutations inABCD1,located atXq28and demonstratesX-linked recessiveinheritance. The geneABCD1encodes a peroxisomal membrane transporter which is responsible for transporting very long chain fatty acid substrate into the peroxisomes for degradation. Mutations in this gene that interfere with this process cause this syndrome.[5]

Males with anABCD1mutation arehemizygous,as they only have a single X chromosome. Female carriers will typically avoid the most severe manifestations of the disease, but often become symptomatic later in life.[1]Although the detection of anABCD1mutation identifies an individual who is affected with a form of ALD, there is nogenotype–phenotype correlation.[6]Within a family, there will often be several different phenotypes, despite the presence of the same causative mutation. In one case, a family with six affected members displayed five different phenotypes.[1]There are no common mutations that cause ALD, most are private or familial. Almost 600[3]different mutations have been identified, approximately half aremissense mutations,one quarter areframeshifts,with in-frame deletions and splicing defects making up the remainder.[1]The incidence of new mutations in ALD (those occurring spontaneously, rather than being inherited from a carrier parent) is estimated at 4.1%, with the possibility that these are due togermline mosaicism.[3]

Pathogenesis

[edit]

The exact cause for the varied collection of symptoms found in the different ALD phenotypes is not clear. Thewhite matterof the brain, theLeydig cellsof thetestesand the adrenal cortex are the most severely affected systems.[1]The excess VLCFA can be detected in almost all tissues of the body, despite the localization of symptoms.[1]The lack of Coenzyme A does not permit the disintegration of the VLCFA, accumulating the same in the white matter, adrenal glands, and the testes more specifically in the Leydig cells not allowing the proper function of these organs. Successful treatment of the demyelination process that affects the brain with either stem cell transplant or gene therapy does not immediately normalize the VLCFA levels in body tissues.[7]The levels of VLCFA can be normalized by treatment withLorenzo's oil,but this does not alter the progression of the disease.[2]It is unclear whether the accumulation of VLCFA is associated with the pathogenesis of the disease in a specific way, or if it is a biochemical phenotype, useful for identification.[1]

Diagnosis

[edit]

The clinical presentation of ALD can vary greatly, making diagnosis difficult. With the variety of phenotypes, clinical suspicion of ALD can result from a variety of different presentations. Symptoms vary based on the disease phenotype, and even within families or between twins.[4]When ALD is suspected based on clinical symptoms, the initial testing usually includes plasma very long chain fatty acid (VLCFA) determination usinggas chromatography-mass spectrometry.The concentration of unsaturated VLCFA, particularly 26 carbon chains is significantly elevated in males with ALD, even prior to the development of other symptoms.[8]Confirmation of ALD after positive plasma VLCFA determination usually involves molecular genetic analysis ofABCD1.In females, where plasma VLCFA measurement is not always conclusive (some female carriers will have normal VLCFA in plasma),[8]molecular analysis is preferred, particularly in cases where the mutation in the family is known.[1][3]Although the clinical phenotype is highly variable among affected males, the elevations of VLCFA are present in all males with anABCD1mutation.[3]

Because the characteristic elevations associated with ALD are present at birth, well before any symptoms are apparent, there have been methods developed[9][10]in the interests of including it innewborn screeningprograms.[11]One of the difficulties with ALD as a disease included in universal newborn screening is the difficulty in predicting the eventual phenotype that an individual will express. The accepted treatment for affected boys presenting with the cerebral childhood form of the disease is abone marrow transplant,a procedure which carries significant risks.[2][7]However, because most affected males will demonstrate adrenal insufficiency, early discovery and treatment of this symptom could potentially prevent complications and allow these patients to be monitored for other treatment in the future, depending on the progression of their disease.[11]

The Loes score is a rating of the severity of abnormalities in the brain found on MRI. It ranges from 0 to 34, based on a point system derived from the location and extent of disease and the presence of atrophy in the brain, either localized to specific points or generally throughout the brain. A Loes score of 0.5 or less is classified as normal, while a Loes score of 14 or greater is considered severe. It was developed by neuroradiologist Daniel J. Loes MD and is an important tool in assessing disease progression and the effectiveness of therapy.[12]

Treatments

[edit]

Dietary therapy

[edit]

Initial attempts at dietary therapy in ALD involved restricting the intake of very-long chain fatty acids (VLCFA). Dietary intake is not the only source for VLCFA in the body, as they are also synthesized endogenously. This dietary restriction did not impact the levels of VLCFA in plasma and other body tissues.[2]After the realization that endogenous synthesis was an important contribution to VLCFA in the body, efforts at dietary therapy shifted to inhibiting these synthetic pathways in the body. TheparentsofLorenzo Odone,a boy with ALD, spearheaded efforts to develop a dietary treatment to slow the progression of the disease. They developed a mixture of unsaturated fatty acids (glycerol trioleateand glyceryl trierucate in a 4:1 ratio), known asLorenzo's oilthat inhibits elongation of saturated fatty acids in the body.[2][7]Supplementation with Lorenzo's oil has been found to normalize the VLCFA concentrations in the body, although its effectiveness at treating the cerebral manifestations of the disease is still controversial and unproven.[13]Trials with Lorenzo's oil have shown that it does not stop the neurological degradation in symptomatic patients, nor does it improve adrenal function,[2]but asymptomatic patients, and speculatively AMN variants without cerebral involvement, as well as female carriers may benefit from early intake of oleic and erucic acids in addition to VLCFA restriction.[14]

Adrenomix®: In 2009, a second-generation mixture was created, adding to the glycerol trioleate (GTO) and trierucateglycerol(GTE),conjugated linoleic acid(CLA) a group of linoleic acid isomers capable of overcoming theblood-brain barrier.CLA, through the activation of peroxisome beta oxidation, increases thecatabolismof pro-inflammatory molecules and ROS, acting as an anti-inflammatory and antioxidant. The use of CLA was initially considered in relation to the ability to inhibitfatty acid synthasetogether with a hypolipidic diet. A group of Italian researchers of the Bambino Gesù Pediatric Hospital in Rome showed that the administration of Adrenomix (GTO, GTE and CLA), in addition to decreasing levels ofVLCFAthroughout the body, reduces neuro inflammation and improves somatosensory evoked potential, found unchanged or worsened with only administration of GTO and GTE.[15]

Aldixyl®: In 2016, based on studies developed in recent years in the field of adrenoleukodystrophy and adrenomyelouropathy, a mixture was developed that adds to GTO, GTE and CLA, a mixture of powerful antioxidants at high dosages containingAlpha lipoic acid(ALA), reduced L- glutathione andVitamin E(α- tocopherol). Researchers at the IDIBELL- Hospital Duran i Reynals in Barcelona have shown that the early administration of a cocktail of powerful antioxidants, able to overcome the blood-brain barrier and thus carry out its activity at theCNSlevel, prevents theoxidative stresstypical of the disease, intervenes on the initial axonal dysfunctions and therefore on locomotor damage.[16]This new mixture, unlike what happened with the administration of GTO and GTE alone, poorly accumulated at the level of the nervous system, enhances the anti-inflammatory activity and reduces the levels of VLCFA in the CNS by combining synergistically the activity of its components. In particular, CLA, in addition to overcoming the blood-brain barrier and regulating at the CNS level the metabolism of VLCFA is able to influence the catabolism of pro-inflammatoryeicosanoidsandlipid peroxidationproducts.[17][18][19][20][21]In this sense, the anti-inflammatory activity of ALA, reduced L-glutathione and Vitamin E is enhanced at the level of the whole body, and not only at the peripheral level as was the case in the past.[22]

Transplant

[edit]

While dietary therapy has been shown to be effective to normalize the very-long chain fatty acid concentrations in the plasma of individuals with ALD,allogeneic hematopoietic stem cell transplantsis the only treatment that can stopdemyelinationthat is the hallmark of the cerebral forms of the disease.[7]In order to be effective, the transplant must be done at an early stage of the disease; if the demyelination has progressed, transplant can worsen the outcome, and increase the rate of decline. While transplants have been shown to be effective at halting the demyelination process in those presenting with the childhood cerebral form of ALD, follow-up of these patients has shown that it does not improve adrenal function.[23]

Gene therapy

[edit]

For patients where an appropriate match for a transplant cannot be found, there have been investigations into the use ofgene therapy.Appropriatevectorsare selected and modified to expresswild typeABCD1,which is then transplanted into the patients using a similar procedure as for a bone marrow or stem cell transplant.[7]Gene therapy has only been tried on a small number of patients, mainly inFrance.These patients were only considered for gene therapy after there was noHLA matchfor a traditional transplant. In two reported cases, the gene therapy was successful, with a resolution of the demyelination process up to two years after the procedure. Although the gene therapy was successful in resolving the neurological symptoms, plasma VLCFA levels remained elevated.[7]

Elivaldogene autotemcelis pending authorization by the European Commission as of May 2021.While this treatment is effective with 90% of patients being free of major functional disabilities after treatment, it costs $3.0 million per treatment and it comes with several adverse effects including mucositis and alopecia.[24][25][26][27]

Adrenal insufficiency

[edit]

Treatment of the adrenal insufficiency that can accompany any of the common male phenotypes of ALD does not resolve any of the neurological symptoms. Hormone replacement is standard for ALD patients demonstrating adrenal insufficiency.[28]Adrenal insufficiency does not resolve with successful transplant; most patients still require hormone replacement.[23]

Epidemiology

[edit]

ALD has not been shown to have an increased incidence in any specific country or ethnic group. In the United States, the incidence of affected males is estimated at 1:21,000. Overall incidence ofhemizygousmales andcarrierfemales is estimated at 1:16,800.[3]The reported incidence in France is estimated at 1:22,000.[1]

Asymptomology

[edit]

There are documented asymptomatic males who present no ALD symptoms well into their 60s and 70s. It's not understood how they can have an ABCD1 gene variant and possess elevated VLCFAs and not exhibit either Cerebral ALD, Adrenal Insufficiency, or Adrenomyeloneuropathy symptoms. Daughters of asymptomatic males become obligate carriers, who may themselves be asymptomatic and who can pass the variant onto their children, which then silently perpetuates ALD. Sons of asymptomatic males only receive their father's Y chromosome and therefore can't inherit ALD.[29]

References

[edit]
  1. ^abcdefghijkMoser, Hugo W.; Smith, Kirby D.; Watkins, Paul A.; Powers, James; Moser, Ann (2001). "131. X-Linked Adrenoleukodystrophy". In Scriver, C.W.; Beaudet, A.L.; Sly, W.S.; Valle, D.; Childs, B.; Kinzler, K.W.; Vogelstein, B. (eds.).Metabolic and Molecular Bases of Inherited Disease.Vol. 2 (8th ed.). New York: McGraw Hill.ISBN978-0-07-136320-4.
  2. ^abcdefgBerger, Johannes; Gärtner, Jutta (December 2006). "X-linked adrenoleukodystrophy: Clinical, biochemical and pathogenetic aspects".Biochimica et Biophysica Acta (BBA) - Molecular Cell Research.1763(12): 1721–1732.doi:10.1016/j.bbamcr.2006.07.010.PMID16949688.
  3. ^abcdefgRaymond GV, Moser AB, Fatemi A (6 April 2023) [Originally published 26 March 1999]. "X-Linked Adrenoleukodystrophy". In Adam MP, Ardinger HH, Pagon RA, Wallace SE, Bean LJ, Stephens K, Amemiya A (eds.).GeneReviews.Seattle: University of Washington, Seattle.ISSN2372-0697.PMID20301491.National Library of Medicine Bookshelf ID NBK1315.
  4. ^ab"#300100 - Adrenoleukodystrophy".Johns Hopkins University. Archived fromthe originalon 2015-09-24.Retrieved2012-06-27.
  5. ^Hung, Kun-Long; Wang, Jinn-Shyan; Keng, Wee Teik; Chen, Hui-Ju; Liang, Jao-Shwann; Ngu, Lock Hock; Lu, Jyh-Feng (September 2013). "Mutational Analyses on X-Linked Adrenoleukodystrophy Reveal a Novel Cryptic Splicing and Three Missense Mutations in the ABCD1 Gene".Pediatric Neurology.49(3): 185–190.doi:10.1016/j.pediatrneurol.2013.04.021.PMID23835273.
  6. ^Smith, Kirby D.; Kemp, Stephan; Braiterman, Lelita T.; Lu, Jyh-Feng; Wei, He-Ming; Geraghty, Michael; Stetten, Gail; Bergin, James S.; Pevsner, Jonathan; Watkins, Paul A. (1999). "X-linked adrenoleukodystrophy: Genes, mutations, and phenotypes".Neurochemical Research.24(4): 521–535.doi:10.1023/a:1022535930009.PMID10227685.S2CID38326524.
  7. ^abcdefCartier, Nathalie; Aubourg, Patrick (27 October 2009)."Hematopoietic Stem Cell Transplantation and Hematopoietic Stem Cell Gene Therapy in X-Linked Adrenoleukodystrophy".Brain Pathology.20(4): 857–862.doi:10.1111/j.1750-3639.2010.00394.x.PMC8094635.PMID20626747.S2CID24182017.
  8. ^abMoser, Ann B.; Kreiter, Nancy; Bezman, Lena; Lu, Shou-En; Raymond, Gerald V.; Naidu, Sakkubai; Moser, Hugo W. (January 1999). "Plasma very long chain fatty acids in 3,000 peroxisome disease patients and 29,000 controls".Annals of Neurology.45(1): 100–110.doi:10.1002/1531-8249(199901)45:1<100::aid-art16>3.0.co;2-u.PMID9894883.S2CID24516921.
  9. ^Sandlers, Yana; Moser, Ann B.; Hubbard, Walter C.; Kratz, Lisa E.; Jones, Richard O.; Raymond, Gerald V. (March 2012). "Combined extraction of acyl carnitines and 26:0 lysophosphatidylcholine from dried blood spots: Prospective newborn screening for X-linked adrenoleukodystrophy".Molecular Genetics and Metabolism.105(3): 416–420.doi:10.1016/j.ymgme.2011.11.195.PMID22197596.
  10. ^Hubbard, Walter C.; Moser, Ann B.; Liu, Anita C.; Jones, Richard O.; Steinberg, Steven J.; Lorey, Fred; Panny, Susan R.; Vogt Jr., Robert F.; Macaya, Daniela; Turgeon, Coleman T.; Tortorelli, S; Raymond, GV (July 2009). "Newborn screening for X-linked adrenoleukodystrophy (X-ALD): Validation of a combined liquid chromatography–tandem mass spectrometric (LC–MS/MS) method".Molecular Genetics and Metabolism.97(3): 212–220.doi:10.1016/j.ymgme.2009.03.010.PMID19423374.
  11. ^abRaymond, Gerald V.; Jones, Richard O.; Moser, Ann B. (16 August 2012). "Newborn Screening for Adrenoleukodystrophy".Molecular Diagnosis & Therapy.11(6): 381–384.doi:10.1007/BF03256261.PMID18078355.S2CID21323198.
  12. ^Loes, Daniel J.; Hite, S; Moser, H; Stillman, A E; Shapiro, E; Lockman, L; Latchaw, R E; Krivit, W (October 1994)."Adrenoleukodystrophy: a scoring method for brain MR observations".American Journal of Neuroradiology.15(9): 1761–1766.PMC8333737.PMID7847225.Archivedfrom the original on September 1, 2015.RetrievedJanuary 17,2013.
  13. ^Moser, Hugo W.; Moser, Ann B.; Hollandsworth, Kim; Brereton, N. Hong; Raymond, Gerald V. (24 August 2007). "'Lorenzo's Oil' Therapy for X-linked Adrenoleukodystrophy: Rationale and Current Assessment of Efficacy ".Journal of Molecular Neuroscience.33(1): 105–113.doi:10.1007/s12031-007-0041-4.PMID17901554.S2CID21333247.
  14. ^Semmler, Alexander; Köhler, Wolfgang; Jung, Hans H; Weller, Michael; Linnebank, Michael (9 January 2014)."Therapy of X-linked adrenoleukodystrophy"(PDF).Expert Review of Neurotherapeutics.8(9): 1367–1379.doi:10.1586/14737175.8.9.1367.PMID18759549.S2CID207195153.Archived(PDF)from the original on 13 April 2021.Retrieved4 January2020.
  15. ^Cappa, M.; Bizzarri, C.; Petroni, A.; Carta, G.; Cordeddu, L.; Valeriani, M.; Vollono, C.; De Pasquale, L.; Blasevich, M.; Banni, S. (2012)."A mixture of oleic, erucic and conjugated linoleic acids modulates cerebrospinal fluid inflammatory markers and improve somatosensorial evoked potential in X-linked adrenoleukodystrophy female carriers".Journal of Inherited Metabolic Disease.35(5): 899–907.doi:10.1007/s10545-011-9432-3.PMC3432215.PMID22189598.
  16. ^López-Erauskin, J.; Fourcade, S.; Galino, J.; Ruiz, M.; Schlüter, A.; Naudi, A.; Jove, M.; Portero-Otin, M.; Pamplona, R.; Ferrer, I.; Pujol, A. (2011)."Antioxidants halt axonal degeneration in a mouse model of X-adrenoleukodystrophy".Annals of Neurology.70(1): 84–92.doi:10.1002/ana.22363.PMC3229843.PMID21786300.
  17. ^Diczfalusy, U.; Alexson, S. E. (1990)."Identification of metabolites from peroxisomal beta-oxidation of prostaglandins".Journal of Lipid Research.31(2): 307–314.doi:10.1016/S0022-2275(20)43216-X.PMID2324649.
  18. ^De Waart, D. R.; Koomen, G. C.; Wanders, R. J. (1994)."Studies on the urinary excretion of thromboxane B2 in Zellweger patients and control subjects: evidence for a major role for peroxisomes in the beta-oxidative chain-shortening of thromboxane B2".Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease.1226(1): 44–48.doi:10.1016/0925-4439(94)90057-4.PMID8155738.
  19. ^Ferdinandusse, S.; Meissner, T.; Wanders, R. J.; Mayatepek, E. (2002)."Identification of the peroxisomal beta-oxidation enzymes involved in the degradation of leukotrienes".Biochemical and Biophysical Research Communications.293(1): 269–273.doi:10.1016/S0006-291X(02)00214-0.PMID12054595.
  20. ^Mayatepek, E.; Lehmann, W. D. (1996)."12- and 15-hydroxyeicosatetraenoic acid are excreted in the urine of peroxisome-deficient patients: evidence for peroxisomal metabolism in vivo".Pediatric Research.39(1): 146–149.doi:10.1203/00006450-199601000-00022.PMID8825400.S2CID20240456.
  21. ^Iannone, A.; Petroni, A.; Murru, E.; Cordeddu, L.; Carta, G.; Melis, M. P.; Bergamini, S.; Casa, L. D.; Cappiello, L.; Carissimi, R.; O'Shea, M.; Bell, D.; De Santis, E.; Banni, S. (2009)."Impairment of 8-iso-PGF(2ALPHA) isoprostane metabolism by dietary conjugated linoleic acid (CLA)".Prostaglandins, Leukotrienes, and Essential Fatty Acids.80(5–6): 279–287.doi:10.1016/j.plefa.2009.02.008.PMID19403295.
  22. ^Restuccia, D.; Di Lazzaro, V.; Valeriani, M.; Oliviero, A.; Le Pera, D.; Colosimo, C.; Burdi, N.; Cappa, M.; Bertini, E.; Di Biase, A.; Tonali, P. (1997)."Neurophysiological abnormalities in adrenoleukodystrophy carriers. Evidence of different degrees of central nervous system involvement".Brain.120(7): 1139–1148.doi:10.1093/brain/120.7.1139.PMID9236627.
  23. ^abPetryk, A; Polgreen, L E; Chahla, S; Miller, W; Orchard, P J (5 March 2012)."No evidence for the reversal of adrenal failure after hematopoietic cell transplantation in X-linked adrenoleukodystrophy".Bone Marrow Transplantation.47(10): 1377–1378.doi:10.1038/bmt.2012.33.PMC4547590.PMID22388279.
  24. ^Liu, Angus (September 19, 2022)."A $3M gene therapy: Bluebird bio breaks its own pricing record with FDA approval of Skysona".Fierce Pharma.RetrievedNovember 1,2023.
  25. ^"Skysona: Pending EC decision".European Medicines Agency(EMA).21 May 2021.Archivedfrom the original on 2 June 2021.Retrieved1 June2021.
  26. ^"Bluebird Bio Receives Positive CHMP Opinion for Skysona (elivaldogene autotemcel, Lenti-D) Gene Therapy for Patients Less Than 18 Years of Age with Early Cerebral Adrenoleukodystrophy (CALD)"(Press release). Bluebird Bio. 21 May 2021.Archivedfrom the original on 2 June 2021.Retrieved1 June2021– via Business Wire.
  27. ^"Elivaldogene autotemcel".SPS - Specialist Pharmacy Service.28 May 2021.Archivedfrom the original on 2 June 2021.Retrieved1 June2021.
  28. ^Poll-The, Bwee; Engelen, Marc (15 March 2012). "Peroxisomal Leukoencephalopathy".Seminars in Neurology.32(1): 042–050.doi:10.1055/s-0032-1306385.PMID22422205.S2CID39152217.
  29. ^"Asymptomatic adrenoleukodystrophy in elderly males | Request PDF".Archivedfrom the original on 2021-04-18.Retrieved2021-02-05.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=Adrenoleukodystrophy&oldid=1229652940"